- |||||||||| Journal: Treatment options for moderate to severe atopic dermatitis. (Pubmed Central) - Nov 13, 2022
Biologics and Jakinibs should be considered before the traditional systemic anti-inflammatory agents. Clinicians should consider a modified step management for AD as they await the development of national and international guideline recommendations for how best to position the biologics and Jakinibs into the AD treatment algorithm.
- |||||||||| Siliq (brodalumab) / Bausch Health, LEO Pharma, Kyowa Kirin
Clinical data, Retrospective data, Journal, Real-world evidence: Real-world clinical outcomes of treatment with brodalumab in patients with moderate-to-severe psoriasis: a retrospective, 24-month experience from four academic dermatology centers in Greece. (Pubmed Central) - Nov 10, 2022 Moreover, therapeutic efficacy was affected by prior biologic treatment exposure, as biologic naïve patients had greater reductions in all scores from baseline following treatment with brodalumab (numerical for mean PASI, significant for mean BSA and DLQI scores). Brodalumab is effective long term, improving disease severity and health-related QoL in patients with moderate-to-severe plaque psoriasis in a real-world setting.
- |||||||||| AMTX-100 / Amytrx Therap, Dovonex (calcipotriol) / LEO Pharma, Novartis
Journal: Genomic control of inflammation in experimental atopic dermatitis. (Pubmed Central) - Nov 9, 2022 P1/2 Consequently, NTCI suppressed skin infiltration by inflammatory cells (eosinophils, macrophages, and CD4 + T lymphocytes), and reduced MC903-evoked proliferation of Ki-67-positive cells. Thus, we highlight the mechanism of action and the potential utility of topical NTCI for treatment of AD undergoing Phase 1/2 clinical trial (AMTX-100 CF, NCT04313400).
- |||||||||| Adbry (tralokinumab) / LEO Pharma, AstraZeneca
P3 data, Journal: Patient-oriented measures for phase 3 studies of tralokinumab for treatment of atopic dermatitis (ECZTRA 1, 2 and 3). (Pubmed Central) - Nov 9, 2022 Thus, we highlight the mechanism of action and the potential utility of topical NTCI for treatment of AD undergoing Phase 1/2 clinical trial (AMTX-100 CF, NCT04313400). Tralokinumab with or without TCS exhibited early and clinically meaningful improvements vs placebo in several PROs, which may be beneficial to patients because atopic dermatitis symptom relief is a key treatment concern for patients.
- |||||||||| Dupixent (dupilumab) / Sanofi, Regeneron, Siliq (brodalumab) / Bausch Health, LEO Pharma, Kyowa Kirin, Tremfya (guselkumab) / J&J
Journal: Eczematous eruption after brodalumab successfully treated with guselkumab and dupilumab. (Pubmed Central) - Nov 5, 2022 In conclusion, treatment with brodalumab did not improve overall sleep problems in real-life patients with plaque psoriasis, suggesting that sleep problems require attention in daily clinical practice (Japan Registry of Clinical Trials identifier, jRCTs031180037). No abstract available
- |||||||||| Savaysa (edoxaban) / Daiichi Sankyo, Fragmin (dalteparin sodium) / Pfizer, Eisai, Innohep (tinzaparin) / LEO Pharma
Risk of Venous Thromboembolism or Hemorrhage Among Individuals with Chronic Kidney Disease Taking a Direct Oral Anticoagulant Compared to Low-Molecular-Weight Heparin after a Hip or Knee Arthroplasty (ENMCC - 295-296) - Nov 4, 2022 - Abstract #ASH2022ASH_3486; A population-based, retrospective cohort study was conducted among adults of age = 66 with CKD undergoing hip or knee arthroplasty who had filled an outpatient DOAC prescription (apixaban, rivaroxaban, dabigatran, edoxaban) after surgery compared to LMWH (enoxaparin, dalteparin, tinzaparin) between January 1, 2010 and December 31, 2020 in Ontario, Canada. Among older adults with CKD, DOAC use was associated with lower VTE and higher hemorrhage risk compared to LMWH following knee or hip arthroplasty.
- |||||||||| Innohep (tinzaparin) / LEO Pharma
Anticoagulation and Antiplatelet Strategies in Non-Critically Ill Patients with Covid-19 (ENMCC - Great Hall AD) - Nov 4, 2022 - Abstract #ASH2022ASH_1512; P3 All participants received enoxaparin except for one participant in the intermediate group who received tinzaparin...No treatment strategy met pre-specified statistical stopping criteria prior to trial closure. Trial registration number: NCT04483960
- |||||||||| clobetasol propionate topical / Generic mfg.
Clinical data, Journal: Impact of topical emollient, steroids alone or combined with calcipotriol, on the immune infiltrate and clinical outcome in psoriasis. (Pubmed Central) - Nov 4, 2022 We have shown the combined topical treatment with Calcipotriol/Betamethasone foam to be effective in reducing cellular influx into lesional skin of psoriasis patients and this effect to be superior to emollient or Betamethasone alone. Its previously described efficacy in the clinic may be attributed to its unique and rapid ability to inhibit both adaptive CD8+ T cell and innate immune neutrophilia influx into the skin, which was not observed for the other treatments.
- |||||||||| Dovonex (calcipotriol) / LEO Pharma, Novartis
Preclinical, Journal: A population of dermal Langerin dendritic cells promote the inflammation in mouse model of atopic dermatitis. (Pubmed Central) - Nov 4, 2022 This study aimed to investigate the contributions of Langerhans cells (LCs), resident dermal Langerin DCs (r-Langerin dDCs), and newly infiltrated inflammatory dermal Langerin DCs (i-Langerin dDCs) in an AD mouse model induced by the topical application of MC903...Furthermore, TSLP contributed to the upregulation of Langerin expression in BM-derived DCs and promoted the maturation of Langerin DCs. In summary, the present study demonstrated that the newly infiltrated inflammatory dermal Langerin DCs were essential for AD development and local TSLP production, and TSLP further promoted the production of BM-derived i-Langerin dDCs, which might maintain AD inflammation.
- |||||||||| Taltz (ixekizumab) / Eli Lilly, Japan Tobacco, Siliq (brodalumab) / Bausch Health, LEO Pharma, Kyowa Kirin, Cosentyx (secukinumab) / Novartis
Journal, Real-world evidence: Efficacy, safety, and drug survival of patients with psoriasis treated with IL-17 inhibitors - brodalumab, ixekizumab, and secukinumab: real-world data from the Czech Republic BIOREP registry. (Pubmed Central) - Nov 1, 2022 Negative predictors for treatment discontinuation were obesity and the number of treatment lines, whereas a positive predictor was the presence of concomitant psoriatic arthritis; sex had no influence. This real-life study demonstrated the effectiveness and good safety profile of all currently available IL-17 inhibitors.
- |||||||||| Journal: Why targeted therapeutics have provided benefit in psoriasis: looking at IL-17 biology. (Pubmed Central) - Nov 1, 2022
Il-17 inhibitors are a very fast and effective treatment against psoriasis; however, fungal infections can occur during their use, due to IL-17 biological functions. Therefore, it should be mandatory to choose the right patients to treat with these monoclonal antibodies in order to have a tailored target therapy for each patient.
- |||||||||| Dovonex (calcipotriol) / LEO Pharma, Novartis
INTERLEUKIN-20 PROMOTES NEURO- INFLAMMATION AND PRURITUS IN ATOPIC DERMATITIS () - Oct 30, 2022 - Abstract #ISAD2022ISAD_148; Topical MC903 treatment in mice ear enhanced IL-20R1 expression in trigeminal sensory ganglia, suggesting an epidermal-driven mechanism for sensitization of sensory IL-20 signaling...In a Mouse model of acute itch, intradermal injection IL-20 and IL-13 elicited significant itch-like behavior, though only when co-injected. Our findings highlight a role of IL-20 signaling in the pathophysiology of AD, thus forming a new basis for the development of a novel antipruritic strategy via interrupting IL-20 epidermal pathways.
- |||||||||| Living network meta-analysis of systemic treatments for atopic dermatitis (Le Centre Sheraton Montréal) - Oct 30, 2022 - Abstract #ISAD2022ISAD_114;
Change in signs with abrocitinib 100 mg and upadacitinib 15 mg were similar to dupilumab. Higher doses of abrocitinib and upadacitinib may be somewhat more efficacious than dupilumab whereas baricitinib and tralokinumab may be less efficacious.
- |||||||||| Therapeutic agents for atopic dermatitis in 2022 and beyond (Le Centre Sheraton Montréal) - Oct 30, 2022 - Abstract #ISAD2022ISAD_105;
Some other systemic drugs with various proposed modes of action are in earlier stages of development. Choosing the right form of treatment for atopic dermatitis is a challenge and a complex issue.
- |||||||||| The future in pediatrics (Le Centre Sheraton Montréal) - Oct 30, 2022 - Abstract #ISAD2022ISAD_27;
Tralokinumab and lebrikizumab will be the next biologics available for children, but others are in trial that may modify disease course, the next frontier...On the horizon and already in use are new tools for collection of patient-reported outcomes and quantitative data, such as wearable sensor devices that can capture a range of quantitative data, including in young babies, related to itch, scratch, skin inflammation and barrier function. Through these new monitoring and therapeutic tools, early and effective intervention can be achieved, ideally reducing disease duration and the risk of development of the many comorbidities associated with AD in children and adolescents
- |||||||||| ARGX-112 / LEO Pharma
Trial completion: An Evaluation of LEO 138559 in Adults With Moderate to Severe Atopic Dermatitis. (clinicaltrials.gov) - Oct 21, 2022 P2a, N=58, Completed, Through these new monitoring and therapeutic tools, early and effective intervention can be achieved, ideally reducing disease duration and the risk of development of the many comorbidities associated with AD in children and adolescents Active, not recruiting --> Completed
- |||||||||| Oxbryta (voxelotor) / Global Blood Therap, Innohep (tinzaparin) / LEO Pharma
TREATMENT OF SICKLE CELL ANEMIA () - Oct 16, 2022 - Abstract #EHOC2022EHOC_53; Further progress also made in the area of bone marrow transplant (including alternative donor pool) and gene therapy /gene editing, with recently published data is very encouraging. Although the prognosis of patients with SCD has improved, due to introduction of vaccination, use of antibiotics prophylaxis and blood transfusions, however still patients are dying prematurely and further work is needed on understanding disease and its manifestation.
- |||||||||| Olumiant (baricitinib) / Incyte, Eli Lilly, Dupixent (dupilumab) / Sanofi, Regeneron, Corectim (delgocitinib) / Japan Tobacco, LEO Pharma, Rohto Pharma
Clinical guideline, Journal: English Version of Clinical Practice Guidelines for the Management of Atopic Dermatitis 2021. (Pubmed Central) - Oct 12, 2022 In the present revised guidelines, descriptions of three new drugs, namely, dupilumab, delgocitinib, and baricitinib, have been added. The guidelines present recommendations to review clinical research articles, evaluate the balance between the advantages and disadvantages of medical activities, and optimize medical activity-related patient outcomes with respect to several important points requiring decision-making in clinical practice.
- |||||||||| Adbry (tralokinumab) / LEO Pharma, AstraZeneca
Meaningful Responses In Tralokinumab-Treated Adolescents With Atopic Dermatitis Not Achieving IGA 0/1 at Week-16 (Exhibit Hall (Upper Concourse); Monitor 17) - Oct 10, 2022 - Abstract #ACAAI2022ACAAI_777; P3 A greater proportion of tralokinumab 300mg patients vs. placebo (35.2% vs. 15.0%) achieved ≥6-point improvement in CDLQI. Conclusion Many tralokinumab-treated adolescents who did not achieve IGA 0/1 at Week 16 and/or used rescue therapy still achieved clinically meaningful improvements in AD signs, symptoms, and/or QoL.
- |||||||||| Spevigo (spesolimab) / Boehringer Ingelheim
Clinical, Journal: Commentary on a Clinical Trial of Spesolimab, a Humanized Anti-interleukin-36 Receptor Monoclonal Antibody, in Generalized Pustular Psoriasis. (Pubmed Central) - Oct 9, 2022 Effisayil 1, a randomized, controlled clinical trial, investigated the efficacy and safety of spesolimab in patients presenting with a GPP flare. In this commentary, we discuss the study design, endpoints, and clinical outcomes of Effisayil 1, which differed from previous clinical trials that investigated other biologic agents (adalimumab, secukinumab, brodalumab, ixekizumab, and guselkumab) in patients with GPP.
|